Evidence map›Paper›PMID 34881208›Full record

ArticleJournal of hepatocellular carcinoma2021

Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort.

Shamar Young, Isa Cam, Mehmet Gencturk, Nathan Rubin, Donna D'souza, Siobhan Flanagan, Jafar Golzarian, Tina Sanghvi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatocellular carcinoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shamar YoungUniversity of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA.ORCID 0000-0002-7967-7166
Isa CamUniversity of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA.
Mehmet GencturkUniversity of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA.
Nathan RubinBiostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-7162-5225
Donna D'souzaUniversity of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA.
Siobhan FlanaganUniversity of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA.
Jafar GolzarianUniversity of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA.
Tina SanghviMinneapolis VA Medical Center, Department of Radiology, Minneapolis, MN, USA.
University of Minnesota · USMinneapolis VA Medical Center · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

backgroundThe purpose of this study is to determine and compare the ability of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), aspartate-aminotransferase-to-lymphocyte ratio (ALRI), systemic-inflammation index (SII) and lymphocyte count to predict oncologic outcomes in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). MATERIALS AND

methodsA single-center retrospective review of 296 patients who were treated for 457 HCCs was performed. Pre- and post-treatment laboratory and treatment outcome variables were collected. Objective radiologic response (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. Patients were categorized into above and below median scores and compared.

resultsThe median pretreatment NLR, PLR, ALRI, SII, and lymphocyte count were 2.7 (range: 0.4-55), 88.3 (range: 0.1-840), 71.8 (range: 0.1-910), 238.1 (range: 0.1-5150.8), and 1 (range: 0.1-5.2) 10

conclusionNLR is predictive of PFS and OS in patients with HCC undergoing TACE and may be superior to other inflammatory scores (PLR, ALRI, and SII) in this setting. However, lymphocyte count may be most predictive of OS.

Indexed as

aspartate-aminotransferase-to-lymphocyte ratiochemoembolizationhepatocellular carcinomaneutrophil-to-lymphocyte ratioplatelet-to-lymphocyte ratiosystemic-inflammation index

Identifiers

PMID34881208
PMCPMC8646226
OpenAlexW3215105073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.